CELCUITY INC. - COMMON STOCK

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

11 ديسمبر 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update

14 نوفمبر 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences

12 نوفمبر 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call

07 نوفمبر 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update

14 أغسطس 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call

07 أغسطس 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Celcuity To Participate in Jefferies Global Healthcare Conference

03 يونيو 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Celcuity Announces Pricing of Underwritten Common Stock Offering

30 مايو 2024 07:36:22 بحسب Nasdaq GlobeNewswire

Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing

30 مايو 2024 07:00:01 بحسب Nasdaq GlobeNewswire

Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update

15 مايو 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call

08 مايو 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Celcuity To Present at Upcoming Needham and Stifel Investor Conferences

04 أبريل 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

27 مارس 2024 16:01:00 بحسب Nasdaq GlobeNewswire

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

20 مارس 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024

06 مارس 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Celcuity to Participate in Cowen’s 44th Annual Health Care Conference

28 فبراير 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer

22 فبراير 2024 16:05:00 بحسب Nasdaq GlobeNewswire

Celcuity Appoints Eldon Mayer as Chief Commercial Officer

20 فبراير 2024 07:05:00 بحسب Nasdaq GlobeNewswire

Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium

06 ديسمبر 2023 08:30:00 بحسب Nasdaq GlobeNewswire

Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium

01 ديسمبر 2023 11:02:45 بحسب Nasdaq GlobeNewswire